Ribociclib shows promise for specific recurrent endometrial cancer subtypes in clinical trial
A phase 2 randomized clinical trial finds no overall survival difference for everolimus/letrozole with ribociclib in recurrent endometrial cancer, but ...
A phase 2 randomized clinical trial finds no overall survival difference for everolimus/letrozole with ribociclib in recurrent endometrial cancer, but ...
A small, single-arm phase II study found a 56.3% response rate with first-line cadonilimab plus PF chemotherapy in 16 patients ...
A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and bevacizumab significantly improves response rates, ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine